| Abstrakt: |
A recent study conducted by researchers at Dow University of Health Sciences in Karachi, Pakistan, explores advancements in the treatment of geographic atrophy (GA), a progressive form of age-related macular degeneration (AMD). The study focuses on the breakthrough drug pegcetacoplan (SYFOVRE), which is a complement inhibitor that targets the C3 complement protein to modulate complement activation. Clinical trials have shown that SYFOVRE effectively reduces the growth of GA lesions compared to a placebo. The FDA has approved SYFOVRE as the first and only definitive therapy for GA, marking a significant milestone in the management of this condition. The study also discusses potential future treatment strategies, including immune-modulating agents and ocular gene therapy, but further research is needed to evaluate the long-term benefits, safety profile, and optimal treatment regimens of SYFOVRE. [Extracted from the article] |
